Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Takeda Pharmaceutical Co Ltd ( - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
TAK
New York
2834
https://www.takeda.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Takeda Pharmaceutical Co Ltd (
Takeda Canada Inc. concludes Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) for LIVTENCITY® (maribavir) for the treatment of adults with a post-transplant cytomegalovirus (CMV) infection
- May 16th, 2024 12:02 pm
Takeda’s dengue vaccine obtains WHO prequalification
- May 16th, 2024 8:51 am
Update: Scilex Holding Says Federal Court Approved Settlement With Takeda Pharmaceutical in Gloperba Patent Dispute
- May 14th, 2024 4:23 pm
Scilex Holding Says Federal Court Approved Settlement With Takeda Pharmaceutical in Gloperba Patent Dispute
- May 14th, 2024 2:01 pm
Takeda to Present Oncology Portfolio and Pipeline Data at the 2024 ASCO Annual Meeting
- May 14th, 2024 12:00 pm
Takeda shells out $100m to license AC Immune’s Phase II Alzheimer’s therapy
- May 13th, 2024 3:22 pm
Takeda nabs option to license Alzheimer’s immunotherapies from AC Immune
- May 13th, 2024 12:02 pm
Takeda Pharmaceutical, AC Immune Agree to Option and Licence Agreement, Including on Alzheimer's Treatment Candidate
- May 13th, 2024 11:26 am
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease
- May 13th, 2024 10:00 am
Catalyst's New CEO Has Big Ideas For The Small Biotech
- May 10th, 2024 1:30 pm
Japan's Takeda Pharma Outlines $900M Overhaul To Boost Growth, As 2023 Profit Fall Over 50%
- May 9th, 2024 7:46 pm
Takeda tackles $900m restructuring plan after generics hurt annual profits
- May 9th, 2024 2:03 pm
Takeda targets ‘efficiency’ in restructuring, pipeline cuts
- May 9th, 2024 11:52 am
Takeda Pharmaceutical Projects Lower Annual Profit After Quarterly Loss
- May 9th, 2024 6:56 am
Takeda Announces FY2023 Full Year Results and FY2024 Outlook, Affirming Commitment to Late-Stage Pipeline Development and Core Operating Profit Margin Expansion
- May 9th, 2024 6:07 am
Protagonist Therapeutics Inc (PTGX) Surpasses Q1 Revenue Estimates with Strategic Collaborations
- May 8th, 2024 1:04 am
Down -6.19% in 4 Weeks, Here's Why Takeda Pharmaceutical Co. (TAK) Looks Ripe for a Turnaround
- Apr 29th, 2024 1:35 pm
Down -5.9% in 4 Weeks, Here's Why Takeda Pharmaceutical Co. (TAK) Looks Ripe for a Turnaround
- Apr 26th, 2024 1:35 pm
HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda
- Apr 26th, 2024 12:30 pm
Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer
- Apr 26th, 2024 12:30 pm
Scroll